RBC Capital cuts Evommune price target to $21 from $29
citing TradingView News, reports RBC Capital cut its Evommune price target to $21.00 per share from $29.00.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.